NCT05632848View on ClinicalTrials.gov

Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

June 15, 2022

Primary Completion Date

October 23, 2024

Study Completion Date

February 21, 2025

Conditions
Triple Negative Breast Cancer
Interventions
DRUG

Chidamide combined with Zimberelimab

Chidamide: 30mg each time, orally, biw; Zimberelimab, 240mg, IV, every 3 weeks.

Trial Locations (1)

510060

Sun Yat-sen University, Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER